Compare Gilead Sciences, Inc. (GILD) vs Tenaris S.A. American Depositary Shares (TS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tenaris S.A. American Depositary Shares — how do they compare? Gilead Sciences, Inc. trades at $155.51 (market cap $183.41B), while Tenaris S.A. American Depositary Shares trades at $58.11 (market cap $29.31B). The key difference: Gilead Sciences, Inc. is far larger — about 6.3× Tenaris S.A. American Depositary Shares's market cap, and Tenaris S.A. American Depositary Shares pays the higher dividend (4.07%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Tenaris S.A. American Depositary Shares for 0 Days on average.
| GILD | TS | |
|---|---|---|
Market Cap | $183.41B | $29.31B |
Volume | 5,557,651 | 802,043 |
Sector | Health | Energy |
52-Week High | $155.80 | $64.02 |
52-Week Low | $117.85 | $34.28 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $206.48B | $26.97B |
Dividend Yield | 2.22% | 4.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $153.54, up 2.07% today, near its consensus price target of $153.13. The stock shows a bullish technical trend with strong moving average signals. Recent earnings beat expectations in Q2 2026, though the company posted a net loss. Revenue growth is steady, with 2025 revenue at $29.44B, but profitability metrics like ROE and net income margin are negative. Positive news includes expanded HIV drug access in Latin America.
The outlook is mixed: analyst consensus is bullish with 65.52% buy ratings, but high debt and negative margins pose risks. Key catalysts include oncology pipeline advances and HIV franchise growth, while execution risks and competitive pressures remain concerns for investors.
Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.
The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tenaris S.A. American Depositary Shares
Tenaris S.A. manufactures seamless and welded steel pipe products, including casing, tubing, and line pipe, for the oil and gas industry and certain industrial applications. The company operates an integrated production network across 17 countries and offers Rig Direct, its integrated supply-chain service for oilfield customers.
Read more on TS →
